Close Menu

More articles about Diagnostics

Roche Diagnostics AmpliChip CYP450 microarray will have to overcome several regulatory obstacles before it can gain market approval from the US Food and Drug Administration....Subscribers: click headline for more

A team of researchers in Italy has identified a trio of gene mutations — two of them novel — believed to be linked to Alzheimer’s disease

Cytyc has appointed Marla Persky to its board of directors, and has announced the resignation of Anna Richo, who has served as a director since 1998.

Applied Biosystems and BergenShaw International have released an updated version of BergenShaw’s Focus Research software.

Roche, Promega Litigation Heats Up With Fresh Salvo Alleging Overcharging Scheme

Future of Roche Dx’s Five Remaining ASRs Unclear
Roche Diagnostics’ forced decision two weeks ago not to sell its AmpliChip CYP450 microarray as an analyte-specific reagent leaves in limbo the fate of five additional chips the Swiss company is to co-develop with Affymetrix.

What kind of an economic impact might the US Food and Drug Administration s pharmacogenomics initiative have on innovation?...Subscribers: click headline for more

Genaissance Pharmaceuticals, a pioneer in using haplotype technologies to draw drug-discovery alliances with some of the biggest names in pharma, now has its sights on a new market...Subscribers: click headline for more

Ardais has appointed Donald Hawthorne president and CEO. He replaces Gregory Phelps, who left Ardais “to pursue other opportunities,” according to Ardais.

What is it with California and pharmacogenomics?...Subscribers: click headline for more

Ivan Richards has been appointed senior director of pharmacology at Sirna Therapeutics, the company said Nov. 4.

Illumina, CombiMatrix


Illumina expects to launch its BeadStation 500G medium-scale genotyping instrument in the second quarter of 2004.

A multi-center team of researchers has identified a previously misdiagnosed or undiagnosed genetic syndrome caused by microduplication.

Genaissance Posts Mild Growth in Q3 Atop Increases in R&D, Loss
Genaissance Pharmaceuticals reported a modest increase in third-quarter revenue amid greater R&D spending and a slight jump in net loss.

The decision by Tepnel Life Sciences to buy Orchid Biosciences diagnostics division will give Orchid a much-needed cash infusion and may close the final chapter in the company s transition from a SNP-genotyping and molecular-diagnostics firm into a forensics and paternity-testing shop...Subscribers: click headline for more

Fulfilling a promise it made to industry this spring, the US Food and Drug Administration this week released for public comment its much-anticipated draft guidance on the submission of certain pharmacogenomics data...Subscribers: click headline for more


As the Canadian election season heats up, neither major party has really paid much attention to science, according to Nature News.

BBC News says the uncertainty over Brexit is affecting science funding in the UK.

A new app purports to tell users "how gay" they are by looking at their DNA, but experts tell Futurism that the app is bunk.

In Nature this week: human and great ape cerebral organoids reveal aspects of brain development unique to humans, and more.